Camelia Savulescu
Overview
Explore the profile of Camelia Savulescu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
433
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Savulescu C, Prats-Uribe A, Brolin K, Uuskula A, Bergin C, Fleming C, et al.
Vaccine
. 2024 Dec;
45:126615.
PMID: 39724693
Introduction: Repeated COVID-19 booster vaccination was recommended in healthcare workers (HCWs) to maintain protection. We measured the relative vaccine effectiveness (rVE) of the second booster dose of COVID-19 vaccine compared...
2.
Garcia Quesada M, Peterson M, Bennett J, Hayford K, Zeger S, Yang Y, et al.
Lancet Infect Dis
. 2024 Dec;
PMID: 39706205
Background: Widespread use of pneumococcal conjugate vaccines (PCVs) has reduced vaccine-type invasive pneumococcal disease (IPD). We describe the serotype distribution of IPD after extensive use of ten-valent PCV (PCV10; Synflorix,...
3.
Bennett J, Knoll M, Kagucia E, Garcia Quesada M, Zeger S, Hetrich M, et al.
Lancet Infect Dis
. 2024 Dec;
PMID: 39706204
Background: Pneumococcal conjugate vaccines (PCVs) that are ten-valent (PCV10) and 13-valent (PCV13) became available in 2010. We evaluated their global impact on invasive pneumococcal disease (IPD) incidence in all ages....
4.
Savulescu C, Prats-Uribe A, Brolin K, Makaric Z, Uuskula A, Panagiotakopoulos G, et al.
Vaccines (Basel)
. 2024 Nov;
12(11).
PMID: 39591197
European countries have included healthcare workers (HCWs) among priority groups for COVID-19 vaccination. We established a multi-country hospital network to measure the SARS-CoV-2 incidence and effectiveness of COVID-19 vaccines among...
5.
Savulescu C, Prats-Uribe A, Brolin K, Uuskula A, Bergin C, Fleming C, et al.
Euro Surveill
. 2024 Nov;
29(44).
PMID: 39484687
COVID-19 vaccination recommendations include healthcare workers (HCWs). We measured COVID-19 vaccine effectiveness (CVE) of the autumn 2023 dose against laboratory-confirmed SARS-CoV-2 infection in a prospective cohort study of 1,305 HCWs...
6.
Merdrignac L, Ait El Belghiti F, Pandolfi E, Acosta L, Fabianova K, Habington A, et al.
Vaccine
. 2024 Mar;
42(9):2370-2379.
PMID: 38472070
Background: Monitoring effectiveness of pertussis vaccines is necessary to adapt vaccination strategies. PERTINENT, Pertussis in Infants European Network, is an active sentinel surveillance system implemented in 35 hospitals across six...
7.
Savulescu C, Krizova P, Valentiner-Branth P, Ladhani S, Rinta-Kokko H, Levy C, et al.
Vaccine
. 2022 May;
40(29):3963-3974.
PMID: 35637067
Background: Pneumococcal conjugate vaccines covering 10 (PCV10) and 13 (PCV13) serotypes have been introduced in the infant immunization schedule of most European countries in 2010-11. To provide additional real-life data,...
8.
Hanquet G, Krizova P, Dalby T, Ladhani S, Nuorti J, Danis K, et al.
Emerg Infect Dis
. 2021 Dec;
28(1):137-138.
PMID: 34932457
We evaluated invasive pneumococcal disease (IPD) during 8 years of infant pneumococcal conjugate vaccine (PCV) programs using 10-valent (PCV10) and 13-valent (PCV13) vaccines in 10 countries in Europe. IPD incidence...
9.
Knoll M, Bennett J, Garcia Quesada M, Kagucia E, Peterson M, Feikin D, et al.
Microorganisms
. 2021 Apr;
9(4).
PMID: 33918127
Serotype-specific surveillance for invasive pneumococcal disease (IPD) is essential for assessing the impact of 10- and 13-valent pneumococcal conjugate vaccines (PCV10/13). The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project...
10.
Hanquet G, Krizova P, Valentiner-Branth P, Ladhani S, Nuorti J, Lepoutre A, et al.
Thorax
. 2018 Oct;
74(5):473-482.
PMID: 30355641
Background: Pneumococcal conjugate vaccines (PCVs) have the potential to prevent pneumococcal disease through direct and indirect protection. This multicentre European study estimated the indirect effects of 5-year childhood PCV10 and/or...